Finance

Lists
ZVRA:NASDAQ
Zevra Therapeutics Inc
$11.12
-1.77%
(-0.20) 1D
Sep 24, 11:36:16 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZVRA...
Open
$11.28
High
$11.32
Low
$11.07
Mkt. cap
660.35M
Avg. vol.
867.10K
Volume
113.62K
P/E ratio
11.61
52-wk high
$15.04
52-wk low
$8.01
EPS
$0.96
Beta
0.95
Shares outstanding
59.38M
No. of employees
61
Open
$11.28
High
$11.32
Low
$11.07
Mkt. cap
660.35M
Avg. vol.
867.10K
Volume
113.62K
P/E ratio
11.61
52-wk high
$15.04
52-wk low
$8.01
EPS
$0.96
Beta
0.95
Shares outstanding
59.38M
No. of employees
61
News stories
From web sources and news partners
About Zevra Therapeutics Inc
CEO-
Employees61
Founded2006
Headquarters-
SectorPharmaceutical industry
Websitezevra.com
Analyst ratings
Based on 9 analysts giving stock ratings to ZVRA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ZVRA in the last 3 months.
Highest
Current $11.12
$35.00 (+214.75%)
Average
$25.25 (+127.07%)
Lowest
$20.00 (+79.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$26.00
+133.8%
09/21/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$20.00
+79.9%
08/11/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$35.00
+214.7%
08/06/2026
Eddie Hickman
Guggenheim
Buy
Maintained
$23.00
+106.8%
08/06/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
$21.00
+88.8%
08/06/2026
Kambiz Yazdi
BTIG
Buy
Maintained
$24.00
+115.8%
08/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
$28.00
+151.8%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$25.00
+124.8%
08/05/2026
Unknown Analyst
Roth MKM
Buy
Maintained
$21.00
+88.8%
05/07/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
03/16/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.25 / $0.18
+41.51%beat
Revenue / Est. (USD)
39.66M / 34.84M
+13.85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
26.06M
34.12M
36.22M
39.66M
Cost of goods sold
1.24M
1.52M
1.90M
1.52M
Cost of revenue
1.24M
1.52M
1.90M
1.52M
Research and development expenses
3.43M
2.52M
4.39M
4.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.94M
20.45M
20.78M
16.56M
Operating expense
20.68M
23.29M
25.49M
21.36M
Total operating expenses
21.92M
24.81M
27.39M
22.89M
Operating income
4.14M
9.32M
8.83M
16.78M
Other non operating income
-5.51M
3.56M
-6.25M
-6.41M
EBT including unusual items
-977.00K
12.67M
44.80M
12.79M
EBT excluding unusual items
-1.10M
12.64M
4.46M
12.93M
Income tax expense
-433.00K
501.00K
6.91M
4.04M
Effective tax rate
44.32%
3.96%
15.43%
31.59%
Other operating expenses
-
-
-
-
Net income
-544.00K
12.16M
37.89M
8.75M
Net profit margin
-2.09%
35.65%
104.61%
22.07%
Earnings per share
-0.01
0.19
0.18
0.25
Interest and investment income
2.31M
1.71M
3.59M
2.56M
Interest expense
-2.05M
-1.95M
-1.71M
-
Net interest expenses
262.00K
-236.00K
1.88M
2.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.54M
9.68M
9.20M
17.14M
Gain or loss from assets sale
-
63.00K
-43.31M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps